Free Trial

Evoke Pharma Q4 2022 Earnings Report

Evoke Pharma logo
$4.82 -0.44 (-8.37%)
As of 02/21/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Evoke Pharma EPS Results

Actual EPS
-$6.36
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Evoke Pharma Revenue Results

Actual Revenue
$0.80 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Evoke Pharma Announcement Details

Quarter
Q4 2022
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Slide Deck

Evoke Pharma Earnings Headlines

StockNews.com Initiates Coverage on Evoke Pharma (NASDAQ:EVOK)
Evoke underscores committment to patients after FDA update on domperidone
$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
See More Evoke Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evoke Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evoke Pharma and other key companies, straight to your email.

About Evoke Pharma

Evoke Pharma (NASDAQ:EVOK), a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

View Evoke Pharma Profile

More Earnings Resources from MarketBeat